Cyclerion Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-5.26	-44.08	-51.65	-77.8	-123.01	-115.25	-93.92	-63.55
Depreciation & Amortization	0	0.07	0.47	2.3	2.7	1.53	1.75	2.17
Share-Based Compensation	1.07	6.25	9.61	14.99	19.63	12.43	9.49	7.18
Other Operating Activities	-17.05	-2.85	5.05	-11.98	-1.54	3.79	1.47	4.33
Operating Cash Flow	-21.25	-40.61	-36.52	-72.49	-102.22	-97.5	-81.22	-49.87
Capital Expenditures	0	0	1.46	0.02	-6.72	-3.44	-1.4	-1.45
Acquisitions	10.4	0	0	0	0	0	0	0
Investing Cash Flow	10.4	0	1.46	0.02	-6.72	-3.44	-1.4	-1.45
Share Issuance / Repurchase	5.02	0.03	30.79	24.58	175.51	0	0	0
Debt Issued / Paid	0	0	0	3.51	0	0	0	0
Other Financing Activities	-	-	-	-	36.06	100.94	82.62	51.32
Financing Cash Flow	5.02	0.03	30.79	28.09	211.57	100.94	82.62	51.32
Exchange Rate Effect	0.01	0	0	-0.01	-0.02	0	0	0
Net Cash Flow	-5.81	-40.58	-4.27	-44.39	102.62	0	0	0
Free Cash Flow	-21.25	-40.61	-35.06	-72.47	-108.93	-100.94	-82.62	-51.32
Free Cash Flow Margin	-	-13673.74%	-889.40%	-3156.45%	-2416.91%	-	-	-
Free Cash Flow Per Share	-9.09	-18.69	-16.19	-42.68	-79.31	-129.78	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).